YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Amgen Inks $10.5 Billion Deal for Onyx

August 26, 2013 | Amgen agreed to acquire Onyx Pharmaceuticals on Sunday for $10.4 billion. Amgen tried to acquire the in June for $120/share, but was rejected. Yesterday's agreement was for $125/share. Onyx, based in South San Francisco, has a drug product designed to fight blood cancers. Los Angeles Times
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.